Abstract Purpose: Regional therapy of primary or metastatic liver cancer with low hepatic extraction ratio drugs such as doxorubicin is constrained by development of systemic toxicity. To examine the eect of augmentation of hepatic drug extraction, a swine model of hepatic artery infusion (HAI) with minimally invasive hepatic venous isolation and hepatic venous drug extraction (HVDE) was developed to study the comparative pharmacokinetic pro®les of regional and systemically administered doxorubicin. Methods: Doxorubicin 0.5±9 mg/kg was administered to 31 pigs over 90 min either by HAI with simultaneous HVDE or by standard systemic vein infusion. Systemic artery and hepatic vein plasma samples were collected periodically (0 to 240 min) for determination of doxorubicin concentrations by high-performance liquid chromatography. Pharmacokinetic pro®les were modeled with PCNON-LIN 4.2. Results: Concentration-time data were best described in all pigs by a two-compartment open model of elimination. Independent of the route of administration, AUC and C max values increased with dose. Mean systemic AUC and C max values were consistently lower with regional administration, with statistically signi®-cant decreases at the 0.5 and 3 mg/kg doses, whereas there was no relationship between hepatic vein parameters and route of administration. There was a linear relationship between mean systemic AUC values and dose in pigs receiving doxorubicin via HAI with HVDE, whereas mean systemic AUC values increased exponentially at doses of 5 mg/kg or above with systemic vein administration. Conclusions: Administration of doxorubicin by HAI with simultaneous HVDE signi®-antly decreases systemic exposure in comparison with standard systemic vein drug infusion, and may protect against nonlinear increases in exposure at higher doses.
Introduction Doxorubicin ( Fig. 1) is an anthracycline antibiotic with potent tumoricidal activity against a broad spectrum of hematologic and solid tumor types, including lymphocytic and nonlymphocytic leukemias, Hodgkin's and non-Hodgkin's lymphomas, sarcomas, germ cell tumors, mesotheliomas, and carcinomas [34] . The tumoricidal activity of doxorubicin is attributed to several distinct DNA-disruptive processes [6, 9, 35, 40] . These processes, many of which are carried out by doxorubicin metabolites generated in the liver, include noncovalent intercalation between 5¢-GC nucleotide base pairs in the DNA helix, classic DNA alkylation reactions, generation of oxygen free radical intermediates, and disruption of DNA repair via inhibition of topoisomerase I and II enzymes [7, 8, 17, 21, 24, 29, 35, 48] . The utility of doxorubicin does not come without a price. Acute adverse eects include dose-limiting leukopenia, alopecia, radiosensitization, venous¯are reactions, and stomatitis [13, 23, 34, 45 ]. An irreversible, cumulative dose-related cardiomyopathy generally limits the use of doxorubicin to a total recommended lifetime dose of 550 mg/m 2 , even against tumors which are responding to therapy [32] .
Regional cancer chemotherapy administration has been investigated with many agents in an attempt to decrease systemic exposure and toxicity [15] . This approach is based on pharmacokinetic principles, with selectivity obtained by increasing the drug concentration at the tumor site while minimizing systemic exposure and toxicity. This selective advantage can be realized if the tumor-bearing organ eliminates a major portion of the chemotherapy dose upon initial exposure (prior to reaching the systemic circulation). Extracorporeal drug removal may be used to augment presystemic drug removal, permitting a selective advantage when using agents not extensively eliminated by the tumor-bearing target tissue [22, 38] . Regional doxorubicin administration by hepatic artery infusion has been employed for treatment of primary and metastatic liver cancer with disappointing results, even though response rates have been promising [1, 10, 12, 26, 36, 49, 51] . Doxorubicin is extensively metabolized by the liver, with biliary excretion of glucuronide conjugates of 7-deoxydoxorubicin-aglycone or doxorubicinol accounting for about 40% of overall excretion [6, 9] . However, the hepatic extraction ratio of doxorubicin is only 45±50% [26] . Regional administration without extracorporeal augmentation of drug removal therefore does not signi®-cantly reduce systemic exposure or toxicity [3, 14, 30] .
This study investigated the pharmacokinetic pro®le of doxorubicin administered by hepatic artery infusion (HAI) with simultaneous hepatic venous isolation and hepatic venous drug extraction (HVDE), a method designed to reduce systemic exposure by enhancing presystemic drug removal [3, 18, 19, 25] . This method does not require laparotomy. It involves delivery of doxorubicin directly to the liver via the hepatic artery, collection of all hepatic venous euent, and ®ltration of drug from euent prior to systemic reinfusion. Previous reports have documented an extraction ratio of 75±91% with this method of doxorubicin administration, associated with a signi®cant reduction in systemic exposure, as measured by area under the plasma concentration versus time curve (AUC), and a decrease in cardiac tissue concentrations of doxorubicin and doxorubicinol [3±5, 27] .
Material and methods

Hepatic venous isolation with hepatic venous drug extraction
A group of 31 female domestic swine (Hodgin's Kennels, Howel, Mich.) weighing 20±37 kg were studied. All procedures were performed in the morning following a 12-h overnight fast. As previously described, hepatic venous isolation was accomplished using a four-lumen double-balloon polyethylene catheter (Fig. 2) [3±5]. After¯uoroscopically guided passage of the catheter into the inferior vena cava, the caudal balloon was in¯ated superior to the renal veins and the cephalad balloon in the suprahepatic vena cava just below the right atrium. Blood was then withdrawn through intra-balloon catheter fenestrations into the main catheter lumen and out to an extracorporeal circuit. This setup allowed collection of all hepatic venous euent. The fourth catheter lumen bypassed the main lumen and permitted blood¯ow from the inferior vena cava below the caudal balloon through the catheter into the suprahepatic vena cava. Fig. 1 The chemical structure of doxorubicin. The inactive 4-ringed aglycone is a substituted naphthacene quinone which is attached at carbon 7 of ring D to the amino sugar daunosamine by a glycosidic bond. Modi®cations of duanosamine alter both toxic and antitumor activity Fig. 2 Schematic representation of the perfusion circuit used to accomplish simultaneous hepatic venous isolation and hepatic venous drug extraction. Hepatic venous euent was collected by a double-balloon catheter placed within the inferior vena cava. Blood was circulated through the extracorporeal circuit by a centrifugal capacitance pump. Blood¯ow in the extracorporeal circuit (equal to hepatic blood¯ow) was measured with an in-line¯ow transducer. In pigs that received doxorubicin by hepatic artery infusion the euent was pumped through a pair of parallel, activated-carbon hemoperfusion ®lters and returned to the pig through a catheter placed within the internal jugular vein. The hemoperfusion ®lters were removed from the extracorporeal circuit in pigs that received peripheral infusions of doxorubicin (used with permission; [3] ) HVDE in the extracorporeal circuit was accomplished with two parallel activated-charcoal hemoperfusion ®lters. HVDE was used in pigs receiving doxorubicin by HAI. The extracorporeal ®lters were bypassed in pigs receiving doxorubicin by systemic infusion (SYSI), leaving systemic distribution of drug undisturbed. Blood from the circuit was returned to the pig through a 12 French internal jugular central venous catheter.
Hepatic venous isolation in pigs receiving doxorubicin via HAI was achieved by in¯ation of the caudal and cephalad balloons prior to initiation of the drug infusion. Blood¯ow through the extracorporeal circuit was maintained with a centrifugal pump, with the rate continuously monitored and adjusted to pump all hepatic venous euent while preventing development of negative pressure sucient to collapse the isolated segment of inferior vena cava or hepatic veins.
All animals were sacri®ced by lethal injection of Beuthanasia-D (Schering-Plough Animal Health, Kenilworth, N.J.) at completion of each study. At the time of sacri®ce, postmortem examination was performed to ensure that the hepatic artery and double-balloon catheters were properly positioned and that no drug extravasation had occurred.
This study was approved by the Subcommittee on Animal Studies of the Ann Arbor Veterans Administration Medical Center.
Doxorubicin administration
Doxorubicin was administered to 14 swine by HAI and to 17 swine by SYSI via the internal jugular vein at doses of 0.5, 1, 3, 5, or 9 mg/kg infused over 90 min. Hepatic venous isolation was performed for 240 min following initiation of HAI or SYSI. In animals receiving doxorubicin via SYSI the hemoperfusion ®lters were omitted from the extracorporeal circuit.
In all experiments, hepatic venous blood samples (from the extracorporeal circuit prior to ®ltration) and systemic artery blood samples (from the internal carotid artery) were collected periodically for determination of doxorubicin and metabolite concentrations. In swine receiving doxorubicin by HAI/HVDE, blood samples were also collected from the extracorporeal circuit before and after ®ltration to allow determination of eciency of drug ®ltration. Samples were obtained at time 0, at 1, 5, 10, 15, 30, 60, and 90 min after initiation of drug infusion, and (after completion of drug infusion) at 91, 95, 100, 105, 120, 150, and 180 min after initiation of the infusion.
Determination of plasma doxorubicin concentrations
Plasma doxorubicin concentrations were determined by highpressure liquid chromatography (HPLC) according to the method of Brenner et al. [11] . Brie¯y, HPLC grade tetrahydrofuran and certi®ed grade ammonium formate, chloroform, and ammonium sulfate were obtained from Fisher Laboratories of Allied Industries (Pittsburgh, Pa.). A doxorubicinol standard was synthesized according to the method of Takanashi and Bachur [46] . Specimens were analyzed following chloroform/isopropanol (1:1 v/v) extraction, with the method modi®ed by the use of a 15-cm lBondapak phenyl column (Waters Associates, Millipore, Milford, Mass.) and a Shimadzu¯uorescence¯ow spectrophotometer. The excitation frequency was 470 nm, with emission measured at 550 nm, permitting a lower limit of detection of doxorubicin in methanol of 0.0005 nM, and 1 ml of pooled human plasma of 0.005 nM. The purity of doxorubicin and doxorubicinol standards was con®rmed by a single HPLC peak at published retention times [11] . At least 95% purity was suggested by the lack of other peaks in the HPLC trace at the sensitivity used.
Pharmacokinetic analysis
The pharmacokinetic parameters area under the plasma concentration versus time curve (AUC), apparent volume of distribution at steady state ( ss ), distribution half-life (t 1a2a ), terminal elimination half-life (t 1a2b ), and total body clearance (CL T ) were estimated from plasma concentration versus time data utilizing nonlinear least squares regression with PCNONLIN 4.2 (SCI Software, Apex, N.C.). The weighted factor in all calculations was the inverse of the square of each plasma concentration. The AUC from time zero to the last measured concentration (180 min) was calculated by the linear trapezoidal rule, with extrapolation to time in®nity obtained by adding this value to the last measurable concentration divided by b (the elimination rate constant obtained from the terminal disposition slope of the plasma concentration versus time curve).
Owing to the observed variability in plasma concentrations during the 90-min infusion period an average``plateau'' maximum plasma concentration (C max ) value was calculated for each pig and used for all further analyses. This average plateau value included the observed plasma concentrations which by visual inspection of the plasma concentration-time curves fell on the plateau region of the curve.
V ss was calculated from the product V c 1 K 12 aK 21 , where V c represents the volume of distribution of the central compartment, K 12 the rate constant describing the movement of doxorubicin from the central compartment to the peripheral compartment, and K 21 the rate constant describing the movement of doxorubicin from the peripheral compartment to the central compartment. The t a was calculated from the quotient (ln 2/a), with a (the distribution rate constant) calculated from plasma concentration versus time data by the method of residuals. The t b was calculated from the quotient (ln 2/b), and CL T from the quotient (dose/AUC).
Unless otherwise indicated, all reported pharmacokinetic parameters are given in the form of mean standard error of the mean (SEM).
Statistical analysis
Mean pharmacokinetic parameters were compared between HAI and SYSI within each dosage cohort by an unpaired Student's t-test, or by a Wilcoxon signed rank's test in the case of parameters which were not normally distributed. Linear regression was used to evaluate the potential relationship between dose and hepatic vein or systemic artery AUC values. A two-tailed P-value less than 0.05 was considered statistically signi®cant for all analyses.
Results
Pharmacokinetic analysis
Of the 31 pigs, 27 survived until at least 90 min after drug infusion had ended. Four deaths occurred in pigs given doxorubicin by SYSI, two of ®ve pigs at the 5 mg/ kg dose and two of two at the 9 mg/kg dose. The pharmacokinetic parameters for SYSI administration at the 9 mg/kg dose reported in Tables 1, 2 , and 3 represent a single pig, which survived 110 min (20 min after the drug infusion ended).
Mean AUC and C max values during HAI and SYSI of doxorubicin are summarized in Table 1 . Other hepatic vein pharmacokinetic parameters are summarized in Table 2 , and systemic artery parameters in Table 3 . Representative mean hepatic vein and systemic artery plasma concentration versus time curves are shown in Fig. 3 . The pharmacokinetic behavior of doxorubicin was best described in all pigs by a two-compartment open model, characterized by rapid distribution to a peripheral compartment (mean t a values ranged from 0.69 0.01 to 33.9 7.47 min) and prolonged elimination from the central (plasma) compartment (mean t b values ranged from 2.07 0.92 to 693 0.06 min).
As shown in Table 1 , mean hepatic vein and systemic artery AUC and C max values increased in a dose-related fashion with either regional or systemic doxorubicin administration. In contrast, as shown in Tables 2 and 3, there was no dose dependence for any other pharmacokinetic parameter in either hepatic vein or systemic artery blood during HAI or SYSI. V ss values were consistently much larger than intravascular volume, with mean values ranging from 173 29.5 to 11 637 10 906 ml/kg, indicating extensive extravascular doxorubicin Hepatic and systemic exposure to doxorubicin
As shown in Table 1 and Fig. 3 , HAI/HVDE resulted in lower systemic drug exposure, as measured by mean AUC and C max values, than did SYSI of an equal dose. These dierences reached statistical signi®cance in the 0.5 and 3 mg/kg dose cohorts. Accordingly, with HAI/ HVDE hepatic vein AUC (AUC HEP )/systemic AUC (AUC SYS ) ratios ranged from 3.88 to 6.71, and hepatic vein C max (C maxHEP )/systemic C max (C maxSYS ) ratios from 3.43 to 8.33, although there were no clear relationships between these ratios and dose. In contrast, the AUC HEP /AUC SYS and C maxHEP /C maxSYS ratios with SYSI ranged from 0.25 to 0.99 and 0.22 to 0.42, respectively. Although the dierences were not signi®cant, lower systemic exposure was consistently associated with greater CL T and shorter t b values. As shown in Table 1 and Fig. 3 , the reduced systemic exposure to doxorubicin with HAI/HVDE did not result in decreased hepatic exposure. Although there was a trend toward higher AUC HEP values with SYSI at higher doses, none of these dierences was statistically signi®cant. In contrast, C maxHEP values were higher with HAI/HVDE at all but the 5 and 9 mg/kg doses; again, none of these dierences reached statistical signi®cance. As shown in Fig. 4 , AUC SYS values rose linearly with dose when doxorubicin was administered by HAI/ HVDE r 0X993Y `0X0001. In contrast, AUC SYS values increased in an exponential fashion with SYSI r 0X999Y `0X001, indicating disproportionate increases in systemic exposure. The curve began to rise steeply at a dose of approximately 5 mg/kg. Two of ®ve pigs given SYSI of doxorubicin at 5 mg/kg, and both pigs that received 9 mg/kg, died within 90 min of ending the infusion. Postmortem examination revealed pulmonary edema and hepatic congestion, suggestive of acute doxorubicin toxicity. In contrast, none of the pigs receiving doxorubicin by HAI/HVDE expired prior to completion of pharmacokinetic sampling at 180 min.
Discussion
At least one-third of all cancer patients develop primary or metastatic liver disease [39, 50] . To overcome the relatively poor response rates of liver tumors to systemic chemotherapy, regional administration of antineoplastic agents has been tried with modest success [20, 28, 31, 37, 42] . Because of its broad spectrum of antitumor activity, there has been particular interest in regional infusion of doxorubicin. Response rates have been promising, but the poor hepatic extraction of this drug limits the utility of this approach since systemic exposure and toxicity remain problematic [1, 2, 10, 12, 26, 36, 49, 51] . The rationale for HAI/HVDE is to improve the pharmacokinetic pro®le by removing drug from hepatic venous blood as it leaves the liver, thereby reducing systemic exposure. This study was designed to characterize the pharmacokinetic pro®le of doxorubicin with this method of administration [3±5, 15, 18, 19, 25] . The plasma concentration versus time pro®les of doxorubicin observed in this study were best described by a two-compartment open model of elimination, whether drug was administered systemically or regionally. This is in agreement with previous studies, which have reported doxorubicin pharmacokinetics to be independent of route of administration [10, 30] . The twocompartment behavior of doxorubicin indicates extensive distribution to an extravascular space (most likely re¯ecting cellular uptake), followed by prolonged redistribution and elimination from the central (plasma) compartment. The systemic t a and t b values observed in our study are in agreement with the results of previous investigators, as are the large V ss values [9, 16, 33] . Previous studies suggest that doxorubicin distributes to tissues in relation to nuclear DNA content, with extensive uptake by the liver, kidneys, heart, lymph nodes, skeletal muscle, fat, and skin [35, 47, 52] . Doxorubicin may be sequestered in fatty tissue, as indicated by a previous study reporting decreased clearance in obese cancer patients [43] . The two-compartment behavior observed with both methods of drug administration in this study is therefore not surprising. Independent of route of administration, cellular uptake and DNA intercalation of doxorubicin, which occurs during the initial distribution phase, is reversible. Redistribution to the plasma compartment ultimately permits liver uptake and biliary excretion. Therefore rapid distribution and prolonged elimination would be expected with HAI/HVDE [34] .
Systemic exposure to doxorubicin, as measured by mean AUC SYS and C maxSYS values, was consistently lower with HAI/HVDE in comparison to SYSI (Table 1) . These dierences reached statistical signi®-cance at the 0.5 and 3 mg/kg doses. In contrast, there were no signi®cant dierences in mean AUC HEP or C maxHEP values, suggesting that decreased systemic exposure was not accompanied by a concomitant decrease in hepatic exposure (Table 1) . Therefore, HAI/HVDE indeed appears to improve the hepatic pharmacokinetic pro®le of doxorubicin administration in comparison with standard SYSI [4, 10, 30, 44] . This pharmacokinetic advantage with HAI/HVDE, which we have previously reported, was illustrated by the AUC HEP /AUC SYS and C maxHEP /C maxSYS ratios, which consistently suggested a decrease in systemic doxorubicin exposure of approximately ®vefold [4] .
Mean systemic CL T values were consistently higher and t b values lower with HAI of doxorubicin, re¯ect-ing the supplemental clearance of drug by HVDE. This is not surprising, given the increase in hepatic doxorubicin extraction ratios (from 50±72% to 75±91%) previously reported with this method of doxorubicin administration [5, 27] . Mean systemic CL T was signi®-cantly increased with HAI/HVDE at the 5 mg/kg dose, although there were no signi®cant dierences in mean systemic t b values. The lack of signi®cance at lower doses in part re¯ects our lack of statistical power, but may also re¯ect the disproportionate increases in AUC and C max values observed with systemic doxorubicin administration at the 5 mg/kg and 9 mg/kg doses (Fig. 4) . In contrast, mean hepatic vein CL T values were slightly lower with regional administration, although none of these dierences was signi®cant. Interestingly, the consistent decrease in mean hepatic vein CL T values with regional doxorubicin administration did not correlate with longer t b values. Mean hepatic vein t b values were consistently shorter with HAI/HVDE, reaching statistical signi®cance at the 1 mg/kg dose. This behavior may re¯ect the contribution of the extracorporeal ®lters to drug extraction, with less drug reaching the systemic circulation and reentering the hepatic circulation.
The relationship between mean systemic artery AUC values and doxorubicin does was linear with HAI/ HVDE r 0X993Y `0X0001. In contrast, the relationship between systemic AUC values and dose with SYSI was exponential r 0X999Y `0X001. While this relationship is based on only a few data points, because of the lethality of high-dose systemic infusions, data obtained from two pigs at the 5 mg/kg dose and one pig at the 9 mg/kg dose that died before they were suitable for formal pharmacokinetic analysis con®rm disproportionate doxorubicin exposure whether measured by AUC or C max . Nonlinear increases in systemic exposure to doxorubicin observed in our study could result clinically in severe toxicity, as the normal routes of detoxi®cation and elimination become saturated [41] . The one pig that received 9 mg/kg by SYSI and survived longer than 90 min after completion of the drug infusion had a systemic AUC at 110 min (just prior to death) of 3889 lM min, a value which was more than threefold higher than the total AUC of any other pig in this study. In contrast, regional administration of doxorubicin, even at the highest dose of 9 mg/kg, did not result in premature death of any pig in the study. Extracorporeal ®ltration of doxorubicin therefore appeared not only to augment drug clearance, but to enhance safety as well, indicating both a pharmacokinetic and pharmacodynamic improvement in doxorubicin disposition. This method of administration may permit regional doxorubicin therapy for primary or metastatic hepatic tumors with higher doses designed to exploit the therapeutic dose-response relationship of the drug while preventing increased systemic toxicity.
In summary, we have demonstrated that the pharmacokinetic pro®le of doxorubicin administered by HAI/HVDE or SYSI is best characterized by a twocompartment model, indicating widespread extravascular distribution of drug with either route of administration. Regional administration resulted in signi®cant reductions in systemic exposure as measured by systemic artery AUC and C max values. In addition, there is evidence that augmentation of drug extraction with extracorporeal ®ltration avoids the dose-dependent nonlinear increase in AUC observed with SYSI. HAI/HVDE may permit safe and eective use of doxorubicin, a drug normally hampered by low hepatic extraction, for regional therapy of primary or metastatic hepatic tumors.
